PT1888113E - Anticorpos de ligação a tweak - Google Patents
Anticorpos de ligação a tweak Download PDFInfo
- Publication number
- PT1888113E PT1888113E PT67602581T PT06760258T PT1888113E PT 1888113 E PT1888113 E PT 1888113E PT 67602581 T PT67602581 T PT 67602581T PT 06760258 T PT06760258 T PT 06760258T PT 1888113 E PT1888113 E PT 1888113E
- Authority
- PT
- Portugal
- Prior art keywords
- binding antibodies
- tweak binding
- tweak
- antibodies
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68514905P | 2005-05-27 | 2005-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1888113E true PT1888113E (pt) | 2014-09-04 |
Family
ID=37482143
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT111917712T PT2460831T (pt) | 2005-05-27 | 2006-05-25 | Anticorpos de ligação a tweak |
PT67602581T PT1888113E (pt) | 2005-05-27 | 2006-05-25 | Anticorpos de ligação a tweak |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT111917712T PT2460831T (pt) | 2005-05-27 | 2006-05-25 | Anticorpos de ligação a tweak |
Country Status (30)
Country | Link |
---|---|
US (2) | US8048422B2 (pt) |
EP (3) | EP2460831B1 (pt) |
JP (4) | JP5175181B2 (pt) |
KR (2) | KR20080023317A (pt) |
CN (3) | CN102441163A (pt) |
AU (1) | AU2006252830B2 (pt) |
BR (1) | BRPI0611414B8 (pt) |
CA (1) | CA2609600C (pt) |
CY (1) | CY1118343T1 (pt) |
DK (2) | DK1888113T3 (pt) |
EA (1) | EA018255B1 (pt) |
ES (2) | ES2507069T3 (pt) |
GE (1) | GEP20115324B (pt) |
HK (3) | HK1116423A1 (pt) |
HU (1) | HUE030701T2 (pt) |
IL (1) | IL187585A (pt) |
IS (1) | IS8693A (pt) |
LT (1) | LT2460831T (pt) |
ME (2) | ME00261B (pt) |
MX (1) | MX339015B (pt) |
NO (1) | NO20076607L (pt) |
NZ (2) | NZ564092A (pt) |
PL (3) | PL2460831T3 (pt) |
PT (2) | PT2460831T (pt) |
RS (1) | RS55888B1 (pt) |
SG (1) | SG162728A1 (pt) |
SI (2) | SI2460831T1 (pt) |
UA (1) | UA96416C2 (pt) |
WO (1) | WO2006130374A2 (pt) |
ZA (1) | ZA200710765B (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
SK10042001A3 (sk) * | 1999-01-15 | 2001-12-03 | Biogen, Inc. | Farmaceutická kompozícia obsahujúca činidlo blokujúce proteín tweak alebo receptor tweak |
EP2301578A3 (en) * | 2002-04-09 | 2012-08-08 | Biogen Idec MA Inc. | Methods for treating TWEAK-related conditions |
EP1811838A4 (en) * | 2004-11-08 | 2009-07-22 | Univ Maryland | TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH |
US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
EP2529619B1 (en) | 2005-02-17 | 2015-09-23 | Biogen MA Inc. | Treating neurological disorders |
US20090068102A1 (en) * | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
WO2008048924A2 (en) * | 2006-10-16 | 2008-04-24 | Biogen Idec Ma Inc. | Biomarkers of multiple sclerosis |
US8685741B1 (en) * | 2007-03-07 | 2014-04-01 | Nestec S.A. | Methods for diagnosing irritable bowel syndrome |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2009149185A2 (en) | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
CN102149825B (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 |
US8093006B2 (en) * | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
NZ621170A (en) | 2009-05-13 | 2015-08-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
CN102612524A (zh) * | 2009-09-01 | 2012-07-25 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
TW201119676A (en) * | 2009-10-15 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
US9096879B2 (en) | 2009-11-24 | 2015-08-04 | Biogen Ma Inc. | Method of supplementing culture media to prevent undesirable amino acid substitutions |
US9068004B2 (en) | 2010-02-04 | 2015-06-30 | University Of Louisville Research Foundation, Inc. | TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration |
CA2803392A1 (en) * | 2010-06-24 | 2011-12-29 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
AU2011293253B2 (en) | 2010-08-26 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
MX343114B (es) | 2010-10-05 | 2016-10-25 | F Hoffmann-La Roche Ag * | Anticuerpos contra la tweak humana y usos de los mismos. |
TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
EP2834273B1 (en) | 2012-04-05 | 2018-08-22 | F.Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
JP2016000003A (ja) * | 2013-04-19 | 2016-01-07 | アステラス製薬株式会社 | 新規抗ヒトtweak抗体 |
WO2015051234A2 (en) | 2013-10-04 | 2015-04-09 | Biogen Idec Ma Inc. | Tweak antagonists for treating lupus nephritis and muscle atrophy |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
MA54070A (fr) | 2018-10-29 | 2021-09-08 | Biogen Ma Inc | Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique |
US20210388096A1 (en) * | 2018-10-31 | 2021-12-16 | Astellas Pharma Inc. | ANTI-HUMAN Fn14 ANTIBODY |
CN112778372A (zh) * | 2019-11-11 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用 |
TW202302648A (zh) * | 2021-03-12 | 2023-01-16 | 美商健生生物科技公司 | Cd79b抗體於自體免疫治療應用之用途 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
IL91501A (en) | 1988-09-02 | 1998-03-10 | Dyax Corp | Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AT396939B (de) * | 1990-05-29 | 1993-12-27 | Alois Dipl Ing Dr Jungbauer | Komplexes virales antigen von hiv-1 bindendes rekombinantes protein |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
DK1820858T3 (da) | 1991-03-01 | 2009-11-02 | Dyax Corp | Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf |
ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
EP0590058B1 (en) * | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
KR100543730B1 (ko) | 1996-08-07 | 2006-01-23 | 바이오겐 아이덱 엠에이 인코포레이티드 | 종양 괴사 인자 관련 리간드 |
US7129061B1 (en) | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
CA2280231A1 (en) | 1997-02-12 | 1998-08-13 | Abbott Laboratories | Member of the tnf family useful for treatment and diagnosis of disease |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
JP2001522584A (ja) | 1997-10-10 | 2001-11-20 | ジェネンテク・インコーポレイテッド | Apo−3リガンドポリペプチド |
JP2002527096A (ja) * | 1998-10-16 | 2002-08-27 | イミュネックス・コーポレーション | 血小板の活性化及び補充の阻害剤 |
AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
SK10042001A3 (sk) | 1999-01-15 | 2001-12-03 | Biogen, Inc. | Farmaceutická kompozícia obsahujúca činidlo blokujúce proteín tweak alebo receptor tweak |
US7309687B1 (en) * | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
US7495086B2 (en) | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
EP1239869B1 (en) | 1999-12-20 | 2013-08-28 | Immunex Corporation | Tweak receptor |
US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
NZ522741A (en) | 2000-05-08 | 2005-06-24 | Biogen Idec Inc | Method for promoting neovascularization using a TWEAK agonist and an angiogenic factor, such as fibroblast growth factor and VEGF |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
EP1317283B1 (en) | 2000-09-14 | 2011-07-06 | Biogen Idec MA Inc. | Tweak receptor agonists as anti-angiogenic agents |
DE60205923T2 (de) | 2001-09-27 | 2006-05-18 | Matsushita Electric Industrial Co., Ltd., Kadoma | Übertragungsverfahren, sendegerät und empfangsgerät |
EP2301578A3 (en) * | 2002-04-09 | 2012-08-08 | Biogen Idec MA Inc. | Methods for treating TWEAK-related conditions |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
WO2005010045A1 (en) | 2003-07-24 | 2005-02-03 | Amgen Inc. | Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor |
EP1566636A1 (en) | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
EP1811838A4 (en) | 2004-11-08 | 2009-07-22 | Univ Maryland | TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH |
US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
US20090068102A1 (en) | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
EP2529619B1 (en) | 2005-02-17 | 2015-09-23 | Biogen MA Inc. | Treating neurological disorders |
KR20150031459A (ko) | 2005-03-07 | 2015-03-24 | 제넨테크, 인크. | Tweak 및 fn14 활성을 조절하는 방법 및 조성물 |
EP1885388B1 (en) | 2005-05-10 | 2013-09-11 | Biogen Idec MA Inc. | Treating and evaluating inflammatory disorders |
WO2006130429A2 (en) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
WO2008048924A2 (en) | 2006-10-16 | 2008-04-24 | Biogen Idec Ma Inc. | Biomarkers of multiple sclerosis |
-
2006
- 2006-05-25 DK DK06760258.1T patent/DK1888113T3/da active
- 2006-05-25 CN CN2011103581313A patent/CN102441163A/zh active Pending
- 2006-05-25 EP EP11191771.2A patent/EP2460831B1/en active Active
- 2006-05-25 ME MEP-2008-354A patent/ME00261B/me unknown
- 2006-05-25 KR KR1020077030638A patent/KR20080023317A/ko active Application Filing
- 2006-05-25 ES ES06760258.1T patent/ES2507069T3/es active Active
- 2006-05-25 JP JP2008513580A patent/JP5175181B2/ja not_active Expired - Fee Related
- 2006-05-25 GE GEAP200610459A patent/GEP20115324B/en unknown
- 2006-05-25 KR KR1020137032481A patent/KR101679468B1/ko active IP Right Grant
- 2006-05-25 PL PL11191771T patent/PL2460831T3/pl unknown
- 2006-05-25 ES ES11191771.2T patent/ES2605945T3/es active Active
- 2006-05-25 PL PL384684A patent/PL218791B1/pl unknown
- 2006-05-25 UA UAA200714838A patent/UA96416C2/uk unknown
- 2006-05-25 SI SI200632111A patent/SI2460831T1/sl unknown
- 2006-05-25 PL PL06760258T patent/PL1888113T3/pl unknown
- 2006-05-25 BR BRPI0611414A patent/BRPI0611414B8/pt not_active IP Right Cessation
- 2006-05-25 NZ NZ564092A patent/NZ564092A/en not_active IP Right Cessation
- 2006-05-25 AU AU2006252830A patent/AU2006252830B2/en not_active Ceased
- 2006-05-25 SI SI200631822T patent/SI1888113T1/sl unknown
- 2006-05-25 SG SG201003724-0A patent/SG162728A1/en unknown
- 2006-05-25 CA CA2609600A patent/CA2609600C/en not_active Expired - Fee Related
- 2006-05-25 DK DK11191771.2T patent/DK2460831T3/en active
- 2006-05-25 CN CN201310054744.7A patent/CN103242447B/zh not_active Expired - Fee Related
- 2006-05-25 EA EA200702643A patent/EA018255B1/ru not_active IP Right Cessation
- 2006-05-25 PT PT111917712T patent/PT2460831T/pt unknown
- 2006-05-25 EP EP06760258.1A patent/EP1888113B1/en active Active
- 2006-05-25 WO PCT/US2006/019706 patent/WO2006130374A2/en active Application Filing
- 2006-05-25 NZ NZ583636A patent/NZ583636A/en not_active IP Right Cessation
- 2006-05-25 ME MEP-354/08A patent/MEP35408A/xx unknown
- 2006-05-25 PT PT67602581T patent/PT1888113E/pt unknown
- 2006-05-25 HU HUE11191771A patent/HUE030701T2/hu unknown
- 2006-05-25 MX MX2013013851A patent/MX339015B/es unknown
- 2006-05-25 RS RS20070462A patent/RS55888B1/sr unknown
- 2006-05-25 CN CN2006800275811A patent/CN101247830B/zh not_active Expired - Fee Related
- 2006-05-25 LT LTEP11191771.2T patent/LT2460831T/lt unknown
- 2006-05-25 EP EP11191813A patent/EP2460832A3/en not_active Withdrawn
-
2007
- 2007-11-22 IL IL187585A patent/IL187585A/en active IP Right Grant
- 2007-11-26 US US11/944,709 patent/US8048422B2/en not_active Expired - Fee Related
- 2007-11-29 IS IS8693A patent/IS8693A/is unknown
- 2007-12-10 ZA ZA200710765A patent/ZA200710765B/xx unknown
- 2007-12-27 NO NO20076607A patent/NO20076607L/no not_active Application Discontinuation
-
2008
- 2008-06-23 HK HK08106966.9A patent/HK1116423A1/xx not_active IP Right Cessation
-
2009
- 2009-02-06 HK HK09101067.7A patent/HK1121072A1/xx not_active IP Right Cessation
-
2011
- 2011-09-09 US US13/228,784 patent/US20120009178A1/en not_active Abandoned
-
2012
- 2012-10-12 HK HK12110085.1A patent/HK1169418A1/zh not_active IP Right Cessation
- 2012-11-22 JP JP2012256386A patent/JP2013040210A/ja not_active Withdrawn
-
2014
- 2014-08-25 JP JP2014170135A patent/JP2014221837A/ja not_active Withdrawn
-
2016
- 2016-10-31 JP JP2016212746A patent/JP6234535B2/ja not_active Expired - Fee Related
- 2016-12-14 CY CY20161101291T patent/CY1118343T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1169418A1 (zh) | 結合 的抗體 | |
HK1218126A1 (zh) | 抗體 | |
IL187106A (en) | Sclerostin binds antibody | |
IL190472A0 (en) | Anti-glypican-3 antibody | |
IL185366A0 (en) | Antibody | |
GB0521991D0 (en) | Siglec-9 binding agents | |
GB0517487D0 (en) | Antibodies | |
PL1871804T3 (pl) | Przeciwciała wiążące CCX-CKR2 | |
EP1896047A4 (en) | ANTI-GFRALPHA3 ANTIBODIES | |
GB0520523D0 (en) | Object binding | |
GB0505489D0 (en) | Antibodies | |
GB0505054D0 (en) | Antibodies | |
GB0512278D0 (en) | Antibodies | |
GB0519883D0 (en) | Antibodies | |
GB0525885D0 (en) | Object binding | |
GB0520934D0 (en) | Object binding | |
GB0500400D0 (en) | Antibody | |
GB0502913D0 (en) | Binding sites | |
GB0625144D0 (en) | Novel binding agents |